Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry partner in host cell protein (HCP) detection and other processes related to impurity detection and analysis. Furthermore, Cygnus now also offers innovative virus removal solutions. Cygnus helps companies develop therapeutic proteins, vaccines, antibodies, plasma derivatives, and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval, and commercial launch.
Cygnus is an industry pioneer responsible for developing and commercializing the first generic test kits for the detection of HCP. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new advancements, including its Antibody Affinity Extraction (AAE) technology and orthogonal HCP analysis methods that integrate mass spectrometry, AAE, and ELISA, and MockV virus removal kits.
Cygnus’ proprietary technology, available through its custom and ready-to-use test programs, sets the gold standard for enabling the development of antibodies and assays for HCP and other bioprocess impurities. Cygnus’ quality management program and processes are ISO-9001: 2015 certified.
Cygnus Technologies, based in Southport, North Carolina, was founded in 1997.
- ELISA kits: host cell protein analysis and bioprocess contaminant Analysis
- DNA detection kits
- Western Blot kits
- Immunogenicity test kits
Bio-Connect is the distributor of Cygnus Technologies in the Benelux.
Reduction of bioprocess impurities to the lowest levels practical requires sensitive and robust analytical methods. Cygnus offers a full menu of ELISA kits and orthogonal testing services for all current host cell expression systems and purification process leachates, such as Protein A.